Sanofi announced the acquisition of London-based biotechnology Vicebio for $1.15 billion upfront with up to $450 million in milestone payments. Vicebio's pipeline includes an experimental bivalent vaccine candidate, VXB-241, targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), currently in Phase 1 trials. The deal enhances Sanofi’s respiratory vaccine offerings beyond mRNA platforms, building on partnerships with Novavax and AstraZeneca. Sanofi intends to leverage Vicebio's molecular clamp technology to develop combination vaccines for respiratory diseases affecting millions worldwide.